文献速递妇科肿瘤

晚期宫颈癌一线降阶梯化疗联合派安普利单抗及安罗替尼的分子与免疫应答关联研究

Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer.
PubMed 文献 · Cancer Discov · 2026-01-01

该多中心单臂II期研究纳入34例PD-L1阳性晚期宫颈癌患者,采用两周期降阶梯铂类化疗联合安罗替尼及派安普利单抗后维持治疗。32例可评估患者中30例(93.8%,95%CI 79.2%-99.2%)获客观缓解,单核RNA测序提示T细胞趋化增殖增强及生发中心B细胞活化与疗效相关,三级淋巴结构高比例者生存更优。

要点

  • 降阶梯化疗联合安罗替尼及派安普利单抗一线治疗晚期宫颈癌客观缓解率达93.8%。
  • 肿瘤浸润T细胞趋化增殖增强及生发中心B细胞活化提示更优疗效。
  • 三级淋巴结构与肿瘤面积比值高者生存更好。

核心结论

  • 一线降阶梯铂类化疗联合安罗替尼及派安普利单抗在晚期宫颈癌中显示出安全性和疗效。

研究设计与样本

  • 多中心单臂II期研究,纳入34例PD-L1阳性持续、复发或转移性宫颈癌患者。
  • 治疗方案为两周期降阶梯铂类化疗联合安罗替尼及派安普利单抗,后续仅用安罗替尼及派安普利单抗维持。

主要发现

  • 32例可评估患者中30例(93.8%,95%CI 79.2%-99.2%)获研究者确认的客观缓解。
  • 单核RNA测序提示肿瘤浸润T细胞趋化性和增殖活性增强。
  • 活化的生发中心B细胞预示最佳治疗反应。
  • 三级淋巴结构-肿瘤面积比值高的患者生存更好。

临床怎么用

  • 该降阶梯方案为晚期宫颈癌患者提供了一种潜在毒性更低的治疗选择。
  • 治疗前可评估三级淋巴结构比例及免疫微环境特征以辅助筛选获益人群。

局限性

  • 单臂设计、样本量小,需随机对照研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The standard of care for advanced cervical cancer includes chemotherapy, antiangiogenic, and/or immune checkpoint blockade regimens. Although effective, it leads to pleiotropic side effects. Deescalation chemotherapy together with immunotargeted therapies has been proven effective and less toxic in other cancers. In this study, we conducted a multicenter, single-arm, phase II study of first-line deescalated platinum-based chemotherapy plus anlotinib and penpulimab, followed by maintenance therapy solely with anlotinib and penpulimab in patients with PD-L1-positive, persistent, recurrent, or metastatic cervical cancer. Of 32 efficacy-evaluable patients, 30 (93.8%, 95% confidence interval, 79.2%-99.2%) had an investigator-confirmed objective response. Single-nucleus RNA sequencing implied enhanced chemotaxis and proliferative activity of tumor-infiltrating T cells, and activated germinal center B cells portended optimal treatment response. Patients with a high tertiary lymphoid structure-to-tumor area ratio exhibited better survival. Our findings lay the groundwork for the feasibility of first-line de-escalated chemotherapy plus anlotinib and penpulimab in patients with metastatic, persistent, or recurrent cervical cancer. SIGNIFICANCE: We recruited 34 patients with advanced cervical cancer receiving two cycles of platinum-based chemotherapy plus anlotinib and penpulimab, followed by maintenance therapy solely with anlotinib and penpulimab, and showed safety and efficacy of this deescalation regimen. This work highlights the potential for personalized treatment strategies and feasibility of reduced-toxicity regimens.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Xu Q, Deng Z, Liu J, et al. Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer. Cancer Discov. 2026. PMID: 41297028. doi:10.1158/2159-8290.CD-25-1315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。